Summary
AC Immune (ACIU) Reports Q3 Loss, Lags Revenue Estimates
AC Immune (ACIU) came out with a quarterly loss of $0.2 per share versus the Zacks Consensus Estimate of a loss of $0.22. This compares to earnings of $0.06 per share a year ago.
Earnings Preview: AC Immune (ACIU) Q3 Earnings Expected to Decline
AC Immune (ACIU) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AC Immune (ACIU) Reports Q2 Loss, Misses Revenue Estimates
AC Immune (ACIU) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.2. This compares to a loss of $0.25 per share a year ago.
Acimmune SA (ACIU) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Acimmune SA ever had a stock split?
Acimmune SA Profile
| Biotechnology Industry | Healthcare Sector | Andrea Pfeifer CEO | NASDAQ (NMS) Exchange | H00263105 CUSIP |
| CH Country | 133 Employees | - Last Dividend | - Last Split | 23 Sep 2016 IPO Date |
Overview
AC Immune SA is a clinical stage biopharmaceutical company engaged in the discovery, design, and development of therapeutic and diagnostic products aimed at combating neurodegenerative diseases caused by protein misfolding. Utilizing its proprietary SupraAntigen and Morphomer platforms, the company focuses on creating vaccines, antibodies, and small molecules that specifically target misfolded proteins associated with various neurodegenerative conditions. Through collaborations with leading pharmaceutical entities and its innovative research in the field, AC Immune SA seeks to address the unmet needs in the treatment and diagnosis of these complex diseases. Founded in 2003, the company is based in Lausanne, Switzerland, showcasing its global reach and commitment to improving patients' lives affected by neurodegenerative diseases.
Products and Services
-
Crenezumab
This humanized, conformation-specific monoclonal antibody is in Phase II clinical trial stage, targeting the treatment of Alzheimer's disease (AD). Crenezumab showcases AC Immune’s focus on addressing the critical need for effective treatments against AD.
-
ACI-24
An anti-Abeta vaccine candidate currently in Phase II clinical study for Alzheimer's disease, and has completed Phase Ib for Down syndrome. ACI-24 demonstrates the company’s innovative approach to vaccine development for neurodegenerative diseases.
-
ACI-35
This anti-Tau vaccine candidate is undergoing Phase Ib/2a clinical study, emphasizing the company's dedication to targeting Tau pathology in neurodegenerative disorders, particularly Alzheimer's disease.
-
Tau-positron emission tomography (PET) imaging tracer
Currently in Phase II clinical study, this diagnostic tool represents AC Immune’s commitment to advancing Alzheimer's disease diagnostics by improving the detection of Tau pathology in patients.
-
Small Molecule Tau Aggregation Inhibitors
These compounds are being researched and developed for Alzheimer's disease and NeuroOrphan indications, showcasing AC Immune’s efforts in creating targeted treatments for a range of neurodegenerative conditions through small molecule therapeutics.
-
Discovery and Preclinical Stage Molecules
Focusing on a range of neurodegenerative diseases, these molecules are under exploration for the development of diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. This effort reflects the company's comprehensive approach to tackle the various aspects of neurodegenerative diseases beyond Alzheimer's.
Contact Information
